Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma A Gynecologic Oncology Group study

Publisher Website
Google Scholar
Abstract
Twenty-five patients with advanced or recurrent endometrial carcinoma no longer amenable to control with surgery, radiotherapy, hormonal therapy or higher-priority chemotherapy were treated with cisplatin 50 mg/m2 i.v. every 3 wk. Only 1 objective response, a partial response, was observed among the 25 patients (4%). Twenty patients (80%) exhibited stable disease for > 1 mo.; 4 patients (16%) progressed < mo. after initiating chemotherapy. Adverse effects included leukopenia (28%), thrombocytopenia (40%), nausea and vomiting (74%), and azotemia (37%). Only 1 patient experienced life-threatening toxicity. Cisplatin thus appears tolerable but only minimally active when given at the dose and schedule tested in patients with endometrical carcinoma who have previously demonstrated progression of disease on chemotherapy with known activity.